Evidence map›Paper›PMID 40645978›Full record

Articlenpj aging2025

Nothobranchius furzeri: a vertebrate model for studying cardiac aging and cellular senescence.

Xueling Ma, Yonghe Ding, David Mondaca-Ruff, Xinyue Zhang, Yu Lu, Baul Yoon, Feixiang Yan, Yanyan Liang, Maryam Moossavi, Xiaolei Xu

Abstract read
In one paragraph

Article in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xueling Ma *Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Yonghe Ding *Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
David Mondaca-RuffDepartment of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Xinyue ZhangSchool of Nursing, Beijing University of Chinese Medicine, Beijing, China.
Yu LuInstitute of Traditional Chinese Medicine Information, China Academy of Traditional Chinese Medicine, Beijing, China.
Baul YoonDepartment of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Feixiang YanDepartment of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Yanyan LiangDepartment of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Maryam MoossaviDepartment of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Xiaolei XuDepartment of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. xu.xiaolei@mayo.edu.

Funding

Epicardial remodeling in cardiomyopathy and cardiac agingR01HL107304 · NHLBI · MAYO CLINIC ROCHESTER · PI Xiaolei Xu · 2011 to 2026
$6.6M
Discovering aging-associated genetic modifiers and therapies for anthracycline-induced cardiotoxicityR01HL176555 · NHLBI · MAYO CLINIC ROCHESTER · PI Nadine Norton, Xiaolei Xu · 2025 to 2026
$1.3M
NHLBI NIH HHS R01 HL107304NHLBI NIH HHS R01 HL176555NIH HHS HL107304 and HL081753
6 · The paper itself

Abstract

African turquoise killifish (Nothobranchius furzeri) is the shortest-lived vertebrate that can be bred in captivity, making it an ideal model organism for aging studies. However, whether the animal can be used for studying cardiac aging and whether cellular senescence contribute to this ageing process remain unclear. Here, we conducted a longitudinal study on the GRZ strain, aiming to identify phenotypic and functional markers for cardiac aging. We found that cardiac ageing in GRZ fish can be measured by comparing fish at 16 weeks to 8 weeks of age, using systemic markers such as body/fin coloration, body weight, BMI, cardiac ageing markers such as EF, E/A ratio, and swimming capacity, and cellular senescence markers such as SA-β-gal staining, p15/p16, γ-H2A.X, and SASP markers. Senolytic treatment with D (Dasatinib) and Q (Quercetin) from 12 to 16 weeks mitigated senescence and decelerated cardiac ageing. Together, our findings established GRZ as a useful vertebrate model for studying cardiac ageing and related cardiac senescence.

Identifiers

PMID40645978
PMCPMC12254275

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.